Blog - Page 964 of 5701 - QualityStocks

FridayJun 03, 2022 2:24 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products…

FridayJun 03, 2022 1:59 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s…

FridayJun 03, 2022 1:38 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) CEO to Appear on Benzinga’s ‘All Access’ Series

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its CEO and chair David Michery are spotlighted during an interview on Benzinga’s All Access Series. The interview is slated for today, June 3, 2022, at 11 a.m. ET. Michery and All Access host Spencer Israel will discuss the company, including its upcoming “Strikingly Different” U.S. test drive tour, which will include stops at 19 cities across the country. Benzinga’s All Access show is a valuable source for those who want to learn more about the latest-trending stocks and investment opportunities. The show features live CEO interviews, due diligence…

FridayJun 03, 2022 10:30 am

Nowigence Inc. (NOWG) Executive Team Embodies Key Leadership Skills as Company Introduces Comprehensive AI Management Platform

Vision, integrity and critical thinking are key skills for an effective executive team The Nowigence executive team has garnered an estimated 80 years of experience in leading companies around the world Company looking to capitalize on $20-billion-plus market opportunity with Pluaris, its cloud-based knowledge management tool A recent Indeed article noting the top skills of an effective executive leadership team listed vision, integrity and critical thinking as among the most important (https://ibn.fm/FDaW6) — all three of which are deeply evident in the top executives at Nowigence Inc. (NOWG). Nowigence is an innovative software-as-a-service (“SaaS”) company focused on developing and bringing…

FridayJun 03, 2022 9:45 am

Correlate Infrastructure Partners Inc. (CIPI) Builds on Data Transparency Platform to Improve ESG Reporting in Renewable Energy Solutions Market

Correlate Infrastructure Partners Inc. (CIPI) is a developer of green energy solutions for commercial clients, playing a role in global efforts to reduce carbon emissions by improving the climate impact of buildings and other business facilities CIPI’s two subsidiaries — Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design) — provide complementary approaches to advising commercial clients on green energy solutions, developing those solutions and financing them Correlate uses modern tools for data analysis that provides clients with ESG-friendly reporting capabilities that are increasingly in demand from investors and regulators A recent report by the SustainAbility Institute by ERM…

FridayJun 03, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure A driving focus of the company’s R&D has been to improve the…

ThursdayJun 02, 2022 3:21 pm

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) Fan Pass Live Elevating Artists’ Careers, Delivering ‘100% More’

Friendable (OTC: FDBL), a mobile technology and marketing company, has created the ultimate “anti-label” 360 artist platform since acquiring Artist Republik and FeaturedX. Artist Bigga$tate, who will be a part of the Iowa Summer Jam Festival, in which Fan Pass Live and its 360 artist platform will be an exclusive sponsor, has chosen the platform as his streaming, merchandise and content partner. Bigga$tate gives the Fan Pass Live team accolades for their support. A recent article quotes him as saying, “Fan Pass Live has been the only sponsor that has truly elevated my career in the way all the other…

ThursdayJun 02, 2022 1:37 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will…

ThursdayJun 02, 2022 12:32 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based therapeutics. Dr. John Krystal, the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of…

ThursdayJun 02, 2022 11:34 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in…

Site Search

Company Search